UK reg­u­la­tor warns of se­vere eye re­ac­tions fol­low­ing use of Sanofi and Re­gen­eron's Dupix­ent

The UK’s Med­i­cines and Health­care Reg­u­la­to­ry Agency (MHRA) on Tues­day warned of some new and se­ri­ous eye-re­lat­ed side ef­fects fol­low­ing the use of Sanofi and Re­gen­eron’s atopic der­mati­tis and asth­ma treat­ment Dupix­ent (dupilum­ab).

While Dupix­ent is al­ready as­so­ci­at­ed with cas­es of con­junc­tivi­tis and al­ler­gic con­junc­tivi­tis, dry eye and with in­fre­quent cas­es of ker­ati­tis and ul­cer­a­tive ker­ati­tis, the MHRA is call­ing on health pro­fes­sion­als to be on the look­out for any of these eye-re­lat­ed side ef­fects as “it is not cur­rent­ly pos­si­ble to pre­dict who may ex­pe­ri­ence the rar­er and most se­vere oc­u­lar ad­verse re­ac­tions, such as ul­cer­a­tive ker­ati­tis.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.